{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=36", "query": { "intervention": "Neoadjuvant therapy", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 2083, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T19:46:09.362Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00262925", "title": "Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2006-06", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2015-05-05", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 58, "location_summary": "Aurora, Illinois • Chicago, Illinois • Joliet, Illinois + 43 more", "locations": [ { "city": "Aurora", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262925" }, { "nct_id": "NCT03412643", "title": "Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Weekly Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Celcuity CELx HSF", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 64, "start_date": "2018-05-14", "completion_date": "2023-10-30", "has_results": false, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 43, "location_summary": "Colton, California • Miami Beach, Florida • Orlando, Florida + 34 more", "locations": [ { "city": "Colton", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Naperville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412643" }, { "nct_id": "NCT01663285", "title": "Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Neoadjuvant Cisplatin and Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2012-09", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Rochester, New York • Portland, Oregon", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663285" }, { "nct_id": "NCT01083316", "title": "Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2009-09", "completion_date": "2020-09-04", "has_results": true, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01083316" }, { "nct_id": "NCT05024552", "title": "Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia With FLT3/ITD Mutation" ], "interventions": [ { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Vyxeos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-02-25", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024552" }, { "nct_id": "NCT00003935", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumors", "Central Nervous System Tumors" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 31, "start_date": "1999-09", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2014-07-28", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003935" }, { "nct_id": "NCT02946008", "title": "Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Radical Prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 17, "start_date": "2017-03-27", "completion_date": "2019-07-12", "has_results": false, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02946008" }, { "nct_id": "NCT01982591", "title": "Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Male Breast Cancer", "Neurotoxicity", "Peripheral Neuropathy", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2011-01-03", "completion_date": "2015-03-24", "has_results": false, "last_update_posted_date": "2017-06-15", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 2, "location_summary": "Paoli, Pennsylvania • Philadelphia, Pennsylvania", "locations": [ { "city": "Paoli", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01982591" }, { "nct_id": "NCT07276880", "title": "Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "HER2-Negative Breast Carcinoma", "Node-positive Breast Cancer" ], "interventions": [ { "name": "Neoadjuvant Pembrolizumab", "type": "DRUG" }, { "name": "low dose neoadjuvant boost", "type": "RADIATION" }, { "name": "High dose neoadjuvant boost", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-03-17", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07276880" }, { "nct_id": "NCT04123379", "title": "Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "BMS-813160", "type": "DRUG" }, { "name": "BMS-986253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 48, "start_date": "2020-03-05", "completion_date": "2028-07-13", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-04T19:46:09.362Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04123379" } ] }